Treatment of Intestinal Capillariasis with Thiabendazole, Bithionol, and Bephenium

George E. WhalenDepartment of Clinical Investigation, U. S. Naval Research Unit No. 2, San Lazaro Hospital and Department of Health, Taipei, Taiwan

Search for other papers by George E. Whalen in
Current site
Google Scholar
PubMed
Close
,
Eugene B. RosenbergDepartment of Clinical Investigation, U. S. Naval Research Unit No. 2, San Lazaro Hospital and Department of Health, Taipei, Taiwan

Search for other papers by Eugene B. Rosenberg in
Current site
Google Scholar
PubMed
Close
,
Robert A. GutmanDepartment of Clinical Investigation, U. S. Naval Research Unit No. 2, San Lazaro Hospital and Department of Health, Taipei, Taiwan

Search for other papers by Robert A. Gutman in
Current site
Google Scholar
PubMed
Close
,
John CrossDepartment of Clinical Investigation, U. S. Naval Research Unit No. 2, San Lazaro Hospital and Department of Health, Taipei, Taiwan

Search for other papers by John Cross in
Current site
Google Scholar
PubMed
Close
,
James W. FreshDepartment of Clinical Investigation, U. S. Naval Research Unit No. 2, San Lazaro Hospital and Department of Health, Taipei, Taiwan

Search for other papers by James W. Fresh in
Current site
Google Scholar
PubMed
Close
,
Thomas StricklandDepartment of Clinical Investigation, U. S. Naval Research Unit No. 2, San Lazaro Hospital and Department of Health, Taipei, Taiwan

Search for other papers by Thomas Strickland in
Current site
Google Scholar
PubMed
Close
, and
Cesar UylangcoDepartment of Clinical Investigation, U. S. Naval Research Unit No. 2, San Lazaro Hospital and Department of Health, Taipei, Taiwan

Search for other papers by Cesar Uylangco in
Current site
Google Scholar
PubMed
Close
Restricted access

Treatment of intestinal capillariasis, a newly recognized disease in man, was evaluated in 26 patients during an epidemic in the Philippines. Before this study, no effective treatment was available and the case mortality rate was high. Capillaria philippinensis parasites were eliminated from all 26 patients treated with thiabendazole, and 24 had dramatic clinical improvement. Long-term therapy with thiabendazole sharply decreased the case mortality rate, from 35% to less than 4%. The relapse rate that used to be high among patients treated less than 1 week was prevented by daily administration of the drug for 3 or 4 weeks. Over 75% of the patients observed for 18 months remained asymptomatic after using thiabendazole.

Author Notes

Presently at Columbia Hospital, Wood Veterans Administration Center and Marquette School of Medicine, 5000 West National Avenue, Milwaukee, Wisconsin 53193.

Please address requests for reprints to Publications Office, NAMRU-2, Box 14, APO San Francisco, California 96263.

Save